China Cord Blood Corporation operates within the Health and allied services sector.
In addition to historical fundamental analyses, the complete report available to purchase compares China Cord Blood with three other
health care providers in Asia:
Human Health Holdings Ltd
of Hong Kong
sales of 480.26 million Hong Kong Dollars [US$61.71 million]
of which 70%
was General practice services),
Cordlife Group Limited
(59.63 million Singapore Dollars [US$43.05 million]
of which 99%
was Banking), and
Green Cross Lab Cell Corp
based in South Korea
(42.42 billion Korean Won [US$37.97 million]
of which 77%
was Clinical Laboratory Services).
During the year ended March of 2016, sales at
China Cord Blood were 663.00 million Chinese Renmimbi (US$96.29 million).
increase of 4.4%
versus 2015, when the company's sales were 635.12 million Chinese Renmimbi.
This was the fifth consecutive year of sales increases at China Cord Blood
(and since 2011, sales have increased a total of 95%).